Anthony Woo

Partner

Hong Kong

Anthony qualified as a solicitor in Australia in 2003, in Hong Kong in 2006, in England and Wales in 2008, and in the Guangdong-Hong Kong-Macao Greater Bay Area of China in 2023. He joined the firm in 2003 and focuses on corporate finance, advising (among others) listed companies and financial institutions, as well as their respective senior management and significant shareholders. His experience covers a wide range of complex capital markets transactions, including initial public offerings (H share listings, Main Board migrations, etc.), public and private M&A, secondary market issuances, joint ventures, private equity investments, and other general commercial work. Anthony has also advised on various regulatory investigations involving listed companies and individuals, in connection with the Hong Kong Stock Exchange, the SFC, and the AFRC. Anthony is fluent in English and Chinese (Mandarin and Cantonese).

Experience

Representative matters

Advising CHTC Fong’s International Company Limited (Stock Code: 641), on its disposal of the entire interest of a wholly-owned subsidiary, the target company and the assignment of a loan owed by the target company to another indirect wholly-owned subsidiary through listing-for-sales at the Shenzhen United Property and Equity Exchange.
Advising CHTC Fong’s International Company Limited (Stock Code: 641), on the land resumption project with the Chinese government which involves the surrender of its land use rights of a land parcel of approximately 133,333.3 m2 located in Zhongshan City, together with the buildings and structures located on such land, to Zhongshan City Land Reserve Centre, a departmental centre under Zhongshan City Natural Resources Bureau. This is in exchange for the cash compensation of approximately HK$341 million.
Advising Fosun Pharma Industrial Pte. Ltd. in the restructuring of Sisram Medical Ltd, a company incorporated in Israel and listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1696.HK). The transaction involves Fosun Pharma (as buyer) acquiring the 44.24% and 27.18% of the issued share capital of Sisram Medical from each of Ample Up Limited and Chindex Medical Limited (as seller).

Recognitions

  • Recognized in the prestigious, client-selected Thomson Reuters Stand-Out Lawyers listing for 2026

  • Ranked in Chambers Global for China Corporate/M&A: Hong Kong-based (International Firms), 2022-2025
  • Ranked in Chambers Greater China Region for Hong Kong Corporate/M&A: Hong Kong-based (International Firms), 2022-2025

Credentials

Education

  • City University of Hong Kong, 2003, PCLL
  • College of Law, New South Wales, Professional Programme
  • University of New South Wales, 2002, Bachelor of Law
  • University of New South Wales, 2002, Bachelor of Commerce

Professional admissions & qualifications

  • New South Wales
  • England and Wales
  • Hong Kong
  • Guangdong-Hongkong-Macao Greater Bay Area of China

Court admissions

  • Supreme Court - New South Wales
  • High Court - Hong Kong
  • Supreme Court - England and Wales

Professional affiliations

  • Member of The Law Society of Hong Kong
  • Member of the Recreation and Sports Committee of The Law Society of Hong Kong
  • Non-practising member of The Law Society of England and Wales

Languages spoken

English, Cantonese, Mandarin, Japanese

News